Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENT: Sequential Entecavir and Peginterferon alfa-2a in HBeAg+ Chronic Hepatitis B
NCT01220596Phase 3Unknown
- Sponsor
- Hanyang University
- Start
- Jun 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of entecavir in Chronic Hepatitis B (CHB), sponsored by Hanyang University. Status: unknown.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01220596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220596.